Clinical course of colorectal cancer who experienced thromboembolism during treatment with anti-angiogenesis agents

Masashi Morimachi,Takeshi Kawakami,Ari Nishimura,Kunihiro Fushiki,Hiromichi Shirasu,Satoshi Hamauchi,Takahiro Tsushima,Akiko Todaka,Tomoya Yokota,Yusuke Onozawa,Hirofumi Yasui,Kentaro Yamazaki

ANNALS OF ONCOLOGY（2022）

引用 0|浏览1

暂无评分

摘要

Anti-angiogenesis agents (AAs) are widely used in combination with cytotoxic agents for metastatic colorectal cancer (mCRC). Thromboembolism (TE) is an occasional adverse event specific to AAs. Once it occurs during treatment with AAs, discontinuation of AAs is recommended. There are few studies to investigate the clinical course of mCRC after TE during treatment with AAs.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要